No Yes Ok

Archive

« Older Entries Newer Entries »

Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States Monday, August 10th, 2015
Hybrigenics’ American clinical expenses eligible to US Orphan Drug tax credit   Paris, 10 August 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, wi [...]
Kiadis Pharma announces it raised an additional € 2.0 million via exercise of the Over-Allotment Option and the end of the stabilisation period in relati... Monday, August 3rd, 2015
Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a recently-listed clinical stage biopharmaceutical company [...]
Kiadis Pharma Announces Full Enrolment of its Phase II Clinical Study with Lead Product, ATIR101™ Thursday, July 30th, 2015
~ The target 23 patients have now been enrolled ~   Amsterdam, the Netherlands, July 30, 2015, 7.00 CEST – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brus [...]
Biotech Update 2015 – A Sunny Afternoon Discussing Stroke, Sleep and “Immorbidity” Wednesday, July 8th, 2015
Amsterdam, July 8, 2015. This year’s Biotech Update seminar, organized by LSP and EY, was again a well-received and well-attended event. The very pleasant and sunny weather which made the post-seminar drinks in the [...]
LSP company Kiadis Pharma listed on euronext through IPO Friday, July 3rd, 2015
A PDF version of Kiadis Pharmas' press release can be found here. [...]
Affimed Added to Russell 2000® Index Tuesday, June 30th, 2015
Heidelberg, Germany, June 30, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Compa [...]
Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial Wednesday, June 24th, 2015
• Unyvero to be used for pathogen identification and patient inclusion at several clinical sites across Europe    Holzgerlingen, Germany, June 24, 2015 -- Curetis AG, a developer of next-level molecular di [...]
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan drug designation in acute myeloid leukemia Monday, June 22nd, 2015
Paris, 22 June 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, to [...]
Probiodrug receives 2015 European Mediscience Award for Best Technology Friday, June 19th, 2015
HALLE/SAALE, Germany, 12 June 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces it has been awarded Bes [...]
Biotech Update Wassenaar Friday, June 19th, 2015
We have seen a very successful year for the life science industry with an historical record number of IPOs and M&A transactions in biotech and medical technologies. Also, the European biotech industry experienced [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States Monday, August 10th, 2015
Hybrigenics’ American clinical expenses eligible to US Orphan Drug tax credit   Paris, 10 August 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, wi [...]
Kiadis Pharma announces it raised an additional € 2.0 million via exercise of the Over-Allotment Option and the end of the stabilisation period in rela... Monday, August 3rd, 2015
Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a recently-listed clinical stage biopharmaceutical company [...]
Kiadis Pharma Announces Full Enrolment of its Phase II Clinical Study with Lead Product, ATIR101™ Thursday, July 30th, 2015
~ The target 23 patients have now been enrolled ~   Amsterdam, the Netherlands, July 30, 2015, 7.00 CEST – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brus [...]
Biotech Update 2015 – A Sunny Afternoon Discussing Stroke, Sleep and “Immorbidity” Wednesday, July 8th, 2015
Amsterdam, July 8, 2015. This year’s Biotech Update seminar, organized by LSP and EY, was again a well-received and well-attended event. The very pleasant and sunny weather which made the post-seminar drinks in the [...]
LSP company Kiadis Pharma listed on euronext through IPO Friday, July 3rd, 2015
A PDF version of Kiadis Pharmas' press release can be found here. [...]
Affimed Added to Russell 2000® Index Tuesday, June 30th, 2015
Heidelberg, Germany, June 30, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Compa [...]
Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial Wednesday, June 24th, 2015
• Unyvero to be used for pathogen identification and patient inclusion at several clinical sites across Europe    Holzgerlingen, Germany, June 24, 2015 -- Curetis AG, a developer of next-level molecular di [...]
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan drug designation in acute myeloid leukemia Monday, June 22nd, 2015
Paris, 22 June 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, to [...]
Probiodrug receives 2015 European Mediscience Award for Best Technology Friday, June 19th, 2015
HALLE/SAALE, Germany, 12 June 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces it has been awarded Bes [...]
Biotech Update Wassenaar Friday, June 19th, 2015
We have seen a very successful year for the life science industry with an historical record number of IPOs and M&A transactions in biotech and medical technologies. Also, the European biotech industry experienced [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund